Loading stock…

Privia Health Group, Inc. (PRVA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Privia Health Group, Inc.

PRVAMarket cap $2.59BPrice $20.3

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Runs a physician-enablement platform that helps independent doctors ditch administrative headaches while staying independent, powering over 4,300 practices. Privia takes a cut of savings and value-based care bonuses instead of charging steep software fees upfront.

In Bastion Portfolios?

52W Return-20%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+16%8

Revenue Forecast

Rev CAGR (1y)+15%7

Rev CAGR (3y)+13%8

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+361%10

EPS Growth Y+2+17%8

EPS Growth Y+3+49%9

Quality

Margins

EBIT Margin2%2

Net Income Margin1%2

Free Cash Flow Margin6%4

Debt

Net Debt/EBITDA-6.710

Efficiency

ROE4%3

ROA2%4

Earnings Stability33

GEAR+AVERAGE35

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)185

P/E Ratio (Forward 3y)135

P/BV3.35

EV Multiples

EV/EBITDA Fwd154

EV/EBIT Fwd461

Yield

Free Cash Flow Yieldna–

Dividend Yieldna–

Momentum

Short term

1 month return-2%7

3 month return-25%1

YTD return-14%3

Mid term

Price vs 52wHigh70%4

1 year return-17%3

Long term

3 year return-13%2

5 year return-5%3

Risk Shield

Price Risk

Beta0.76

Volatility32%6

Free Cash Flow

Free Cash Flow Margin6%4

Free Cash Flow Yieldna–

Quality

ROCE6%4

Earnings Stability33

Net Debt/EBITDA-6.710

02Growth

Is it actually growing, and how fast?

PRVAPrivia Health Group

Revenue FY25$2.1B

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+15%7

Revenue, next 3Y, CAGR+13%8

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+361%10

EPS growth, FY27E+17%8

EPS growth, FY28E+49%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 13%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 49%/yr vs revenue 13%/yr), so margins should widen.

WATCH

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 13%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK15 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return-25%1

YTD return-14%3

MID & LONG-TERM▾SCORE

% of 52-week high70%4

1-year return-17%3

3-year return-13%2

5-year return-5%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-13% over three years and -4.8% over five), behind 70% of the market.

It's down 17% over the past year, now 30% below its 52-week high. That is a touch behind the market.

The stock is underperforming over three months (-25%) and so far this year (-14%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Privia Health Group, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PRVAPrivia Health Group

Revenue FY25$2.1B

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+15%7

Revenue, next 3Y, CAGR+13%8

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+361%10

EPS growth, FY27E+17%8

EPS growth, FY28E+49%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 13%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 49%/yr vs revenue 13%/yr), so margins should widen.

WATCH

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 13%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK15 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return-25%1

YTD return-14%3

MID & LONG-TERM▾SCORE

% of 52-week high70%4

1-year return-17%3

3-year return-13%2

5-year return-5%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-13% over three years and -4.8% over five), behind 70% of the market.

It's down 17% over the past year, now 30% below its 52-week high. That is a touch behind the market.

The stock is underperforming over three months (-25%) and so far this year (-14%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Privia Health Group, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community